Evidence map›Paper›PMID 40809817›Full record

ArticlePatient preference and adherence2025

Understanding Patient Perspectives in Treatment and Management of Care in Asthma.

Alexandra Hicks, Michael J George, Mason Benjamin, Eric Lacoste, Hilarry C Orr, Angel Melendez, Donna D'laine Gardner

Abstract read
In one paragraph

Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexandra HicksImmunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, MA, USA.
Michael J GeorgePatient Informed Development and Health Value Translation, Sanofi, Bridgewater, NJ, USA.
Mason BenjaminPatient Informed Development and Health Value Translation, Sanofi, Bridgewater, NJ, USA.
Eric LacosteGlobal CMC Development, Sanofi, Vitry-sur-Seine, France.
Hilarry C OrrPatient Author, New Philadelphia, OH, USA.
Angel MelendezPatient Author, El Paso, TX, USA.
Donna D'laine GardnerAllergy and Asthma Network, Fairfax, VA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: For the development of novel and efficacious drugs and improvement of patients' quality of life, the involvement of patient stakeholders in drug development is essential. This study was conducted among patients with asthma to understand their unmet needs with current treatments, and expectations from new treatments. Methods: Sanofi collaborated with the Allergy & Asthma Network (AAN), a US-based patient advocacy group and their patient community. Several virtual patient panels were conducted involving patient advocates and researchers that spanned patient experiences with asthma, treatment options, gaps, needs, and priorities. Additionally, a literature search was conducted using Medline Results: Based on input gleaned from patients (n=5), their major unmet needs included: management of medication-related side effects, lack of information about correct inhaler techniques, medication costs, misunderstanding of medication dosing schedules, lack of communication between researchers and patients, lack of awareness about patient advocacy organizations and research led programs, and fear of discrimination or having concerns disregarded by healthcare providers. Patients expressed their expectation that new treatments should treat all asthma symptoms, including inflammation, airway constriction, and responsiveness to asthma triggers, all with a single treatment. For patients, an ideal treatment would not need to be taken daily, would be quick-acting, and cost-effective for all patients regardless of their insurance status or coverage. Digital applications that remind patients to take their medications on schedule and monitor asthma triggers, mood, sleep, peak flow recordings, and nutrition could improve patients' treatment adherence, quality of life, and health outcomes would be welcomed. Conclusion: This study emphasizes the importance of gathering input from patients living with asthma, understanding their unmet needs, and the importance of integrated patient engagement in the development of new therapies for asthma.

Indexed as

asthmapatient advocacy groupspatient-focused drug development

Identifiers

PMID40809817
PMCPMC12348883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.